Breaking News Instant updates and real-time market news.

AET

Aetna

$114.46

0.99 (0.87%)

, MRK

Merck

$63.90

1.13 (1.80%)

08:47
10/11/16
10/11
08:47
10/11/16
08:47

Aetna, Merck announce value-based contract for Januvia and Janumet

Aetna (AET) announced that it has entered into a value-based agreement with Merck (MRK) for the type 2 diabetes medications Januvia and Janumet. Under this agreement, Merck's rebates on Januvia and Janumet will be based in part on those products' contributions to helping Aetna's commercial member population with type 2 diabetes achieve or maintain treatment objectives. In a separate initiative, Merck is also collaborating with Aetna on AetnaCare, a new health approach which uses predictive analytics to identify target populations and proactively curate various health and wellness services that are available to each member. "Working with a patient's physicians and other caregivers, the program is designed to support treatment adherence, ensure that critical social support needs are met, and reinforce healthy lifestyle behaviors. The AetnaCare program will initially target patients with diabetes and hypertension in Mid-Atlantic markets," the companies stated. Merck has used its insights and experience to develop educational resources and tools to help address patient engagement, patient behavior and treatment adherence. Aetna will incorporate some of these resources from Merck's inventory into AetnaCare to support more effective patient self-management, the companies explained.

AET

Aetna

$114.46

0.99 (0.87%)

MRK

Merck

$63.90

1.13 (1.80%)

  • 25

    Oct

  • 06

    Nov

  • 10

    Nov

AET Aetna
$114.46

0.99 (0.87%)

09/29/16
PACS
09/29/16
DOWNGRADE
PACS
Underweight
Pacific Crest cuts Fitbit to sell, sees share downside to $11
Pacific Crest analyst Brad Erickson downgraded Fitbit (FIT) to Underweight from Sector Weight after his channel checks indicated that Charge 2, the company's flagship holiday product, is off to a slow start. Underweight is Pacific Crest's equivalent of a sell rating. Charge 2 inventory is accumulating in the channel and sell-through is below initial Blaze/Alta levels, Erickson tells investors in a research note. The analyst continues to believe that a large portion of Fitbit owners stop using the device within months. Further, he views the corporate wellness deal between Aetna (AET) and Apple (AAPL) as a "substantial negative" for Fitbit. Erickson sees downside to $11 for shares of Fitbit. The stock closed yesterday up 17c to $16.70.
09/22/16
EVER
09/22/16
INITIATION
Target $128
EVER
Buy
Aetna initiated with a Buy at Evercore ISI
Evercore ISI analyst Michael Newshel initiated Aetna with a Buy and a $128 price target.
08/25/16
COWN
08/25/16
NO CHANGE
COWN
Managed Care mergers unlikely to close, says Cowen
Cowen analyst Christine Arnold believes the current managed care mergers including Aetna (AET) and Humana (HUM) and Anthem (ANTM) and Cigna (CI) are unlikely to close. The analyst said the government's ability to appeal could extend the litigation process beyond the termination dates stipulated in the merger agreements. Arnold believes the Aetna/Humana merger has a better chance of closing relative to the Anthem/Cigna deal, but believes neither are likely to close.
08/22/16
LEER
08/22/16
NO CHANGE
LEER
Leerink less positive that Anthem challenge to DOJ lawsuit will be successful
Following a conference call with an anti-trust specialist, Leerink analyst Ana Gupte is less positive that the Anthem (ANTM) challenge to the lawsuit by the DOJ will be successful. The analyst says that the specialist views the obstacles to a defense by Anthem-Cigna (CI) to the anti-trust concerns as too numerous to result in a successful close. Further, the analyst believes that any favorable decision, however unlikely, on the merger close, will likely be appealed by the DOJ. Nonetheless, the lower likelihood of this defense being successful may improve the odds of a successful Aetna (AET)-Humana (HUM) defense, the analyst notes.
MRK Merck
$63.90

1.13 (1.80%)

10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.

TODAY'S FREE FLY STORIES

AAPL

Apple

$143.64

1.37 (0.96%)

, CBS

CBS

$65.95

-0.89 (-1.33%)

08:25
04/25/17
04/25
08:25
04/25/17
08:25
Periodicals
Apple Music delays release of first series 'Carpool Karaoke,' Reuters reports »

Apple's Apple Music…

AAPL

Apple

$143.64

1.37 (0.96%)

CBS

CBS

$65.95

-0.89 (-1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 04

    May

  • 15

    Jun

WAT

Waters

$160.27

1.75 (1.10%)

08:25
04/25/17
04/25
08:25
04/25/17
08:25
Earnings
Waters sees Q2 EPS $1.65-$1.75, consensus $1.67 »

Sees strong mid-single…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

08:25
04/25/17
04/25
08:25
04/25/17
08:25
Conference/Events
The Washington Journal holds a discussion on Dodd-Frank »

Manhattan Institute…

WHR

Whirlpool

$174.80

3.29 (1.92%)

08:22
04/25/17
04/25
08:22
04/25/17
08:22
Hot Stocks
Whirlpool sees 3%-5% annual organic net sales growth, 10%+ EBIT margin by 2020 »

Says fundamentals of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

$DJT

DJ Transportation Average

08:21
04/25/17
04/25
08:21
04/25/17
08:21
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

08:20
04/25/17
04/25
08:20
04/25/17
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

08:20
04/25/17
04/25
08:20
04/25/17
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$167.06

2.65 (1.61%)

08:20
04/25/17
04/25
08:20
04/25/17
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:20
04/25/17
04/25
08:20
04/25/17
08:20
General news
U.S. chain store sales rose 0.6% in the week ended April 22 »

U.S. chain store sales…

XLK

Technology Select Sector SPDR

$53.80

0.63 (1.18%)

08:19
04/25/17
04/25
08:19
04/25/17
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$43.28

0.21 (0.49%)

08:19
04/25/17
04/25
08:19
04/25/17
08:19
Hot Stocks
Coca-Cola sees FY17 net CapEx $2B-$2.5B »

Sees FY17 net share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 09

    May

XLE

Energy Select Sector SPDR

$68.19

0.4 (0.59%)

08:19
04/25/17
04/25
08:19
04/25/17
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$88.82

0.57 (0.65%)

08:19
04/25/17
04/25
08:19
04/25/17
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNE

Sony

$33.82

0.14 (0.42%)

08:19
04/25/17
04/25
08:19
04/25/17
08:19
Initiation
Sony initiated  »

Sony initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 25

    May

XLB

S&P Select Materials SPDR

$52.80

0.6 (1.15%)

08:19
04/25/17
04/25
08:19
04/25/17
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COH

Coach

$39.30

0.19 (0.49%)

08:18
04/25/17
04/25
08:18
04/25/17
08:18
Recommendations
Coach analyst commentary  »

Coach risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$52.00

0.27 (0.52%)

08:18
04/25/17
04/25
08:18
04/25/17
08:18
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$55.50

0.5 (0.91%)

08:18
04/25/17
04/25
08:18
04/25/17
08:18
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$74.41

0.73 (0.99%)

08:18
04/25/17
04/25
08:18
04/25/17
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALK

Alaska Air

$90.68

1.57 (1.76%)

, VA

Virgin America

08:18
04/25/17
04/25
08:18
04/25/17
08:18
Hot Stocks
Alaska Air and Virgin America to move into terminal 7 at JFK airport »

Alaska Airlines (ALK) and…

ALK

Alaska Air

$90.68

1.57 (1.76%)

VA

Virgin America

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 04

    May

  • 10

    May

IWM

iShares Trust Russell 2000 Index Fund

$138.92

1.71 (1.25%)

08:18
04/25/17
04/25
08:18
04/25/17
08:18
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$43.28

0.21 (0.49%)

08:17
04/25/17
04/25
08:17
04/25/17
08:17
Hot Stocks
Coca-Cola CEO says Q1 results 'in line with our plan' »

Muhtar Kent, Chairman and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 09

    May

DIA

Diamonds Fund ETF

$207.38

2.13 (1.04%)

08:17
04/25/17
04/25
08:17
04/25/17
08:17
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$237.17

2.58 (1.10%)

08:17
04/25/17
04/25
08:17
04/25/17
08:17
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$23.68

0.52 (2.25%)

08:17
04/25/17
04/25
08:17
04/25/17
08:17
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.